CONTEXT: We wanted to investigate vitamin D in low-risk prostate cancer. OBJECTIVES: The objective of the study was to determine whether vitamin D(3) supplementation at 4000 IU/d for 1 yr is safe and would result in a decrease in serum levels of prostate-specific antigen (PSA) or in the rate of progression. DESIGN: In this open-label clinical trial (Investigational New Drug 77,839), subjects were followed up until repeat biopsy. SETTING: All subjects were enrolled through the Medical University of South Carolina and the Ralph H. Johnson Veterans Affairs Medical Center, both in Charleston, SC. PATIENTS AND OTHER PARTICIPANTS: All subjects had a diagnosis of low-risk prostate cancer. Fifty-two subjects were enrolled in the study, 48 completed 1 yr of supplementation, and 44 could be analyzed for both safety and efficacy objectives. INTERVENTION: The intervention included vitamin D(3) soft gels (4000 IU). MAIN OUTCOME MEASURES: Adverse events were monitored throughout the study. PSA serum levels were measured at entry and every 2 months for 1 yr. Biopsy procedures were performed before enrollment (for eligibility) and after 1 yr of supplementation. RESULTS: No adverse events associated with vitamin D(3) supplementation were observed. No significant changes in PSA levels were observed. However, 24 of 44 subjects (55%) showed a decrease in the number of positive cores or decrease in Gleason score; five subjects (11%) showed no change; 15 subjects (34%) showed an increase in the number of positive cores or Gleason score. CONCLUSION: Patients with low-risk prostate cancer under active surveillance may benefit from vitamin D(3) supplementation at 4000 IU/d.
CONTEXT: We wanted to investigate vitamin D in low-risk prostate cancer. OBJECTIVES: The objective of the study was to determine whether vitamin D(3) supplementation at 4000 IU/d for 1 yr is safe and would result in a decrease in serum levels of prostate-specific antigen (PSA) or in the rate of progression. DESIGN: In this open-label clinical trial (Investigational New Drug 77,839), subjects were followed up until repeat biopsy. SETTING: All subjects were enrolled through the Medical University of South Carolina and the Ralph H. Johnson Veterans Affairs Medical Center, both in Charleston, SC. PATIENTS AND OTHER PARTICIPANTS: All subjects had a diagnosis of low-risk prostate cancer. Fifty-two subjects were enrolled in the study, 48 completed 1 yr of supplementation, and 44 could be analyzed for both safety and efficacy objectives. INTERVENTION: The intervention included vitamin D(3) soft gels (4000 IU). MAIN OUTCOME MEASURES: Adverse events were monitored throughout the study. PSA serum levels were measured at entry and every 2 months for 1 yr. Biopsy procedures were performed before enrollment (for eligibility) and after 1 yr of supplementation. RESULTS: No adverse events associated with vitamin D(3) supplementation were observed. No significant changes in PSA levels were observed. However, 24 of 44 subjects (55%) showed a decrease in the number of positive cores or decrease in Gleason score; five subjects (11%) showed no change; 15 subjects (34%) showed an increase in the number of positive cores or Gleason score. CONCLUSION:Patients with low-risk prostate cancer under active surveillance may benefit from vitamin D(3) supplementation at 4000 IU/d.
Authors: Michael V Young; Gary G Schwartz; Lilin Wang; Daniel P Jamieson; Lyman W Whitlatch; John N Flanagan; Bal L Lokeshwar; Michael F Holick; Tai C Chen Journal: Carcinogenesis Date: 2004-01-16 Impact factor: 4.944
Authors: E Abe; C Miyaura; H Sakagami; M Takeda; K Konno; T Yamazaki; S Yoshiki; T Suda Journal: Proc Natl Acad Sci U S A Date: 1981-08 Impact factor: 11.205
Authors: Pentti Tuohimaa; Leena Tenkanen; Merja Ahonen; Sonja Lumme; Egil Jellum; Göran Hallmans; Pär Stattin; Sverre Harvei; Timo Hakulinen; Tapio Luostarinen; Joakim Dillner; Matti Lehtinen; Matti Hakama Journal: Int J Cancer Date: 2004-01-01 Impact factor: 7.396
Authors: Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman Journal: N Engl J Med Date: 2004-05-27 Impact factor: 91.245
Authors: Shweta Dambal; Angeline A Giangreco; Andres M Acosta; Andrew Fairchild; Zachary Richards; Ryan Deaton; Dennis Wagner; Reinhold Vieth; Peter H Gann; Andre Kajdacsy-Balla; Theodorus Van der Kwast; Larisa Nonn Journal: J Steroid Biochem Mol Biol Date: 2017-01-12 Impact factor: 4.292
Authors: Gary Hardiman; Stephen J Savage; E Starr Hazard; Robert C Wilson; Sean M Courtney; Michael T Smith; Bruce W Hollis; Chanita Hughes Halbert; Sebastiano Gattoni-Celli Journal: Pharmacogenomics Date: 2016-06-30 Impact factor: 2.533
Authors: Yaw A Nyame; Adam B Murphy; Diana K Bowen; Gregory Jordan; Ken Batai; Michael Dixon; Courtney M P Hollowell; Stephanie Kielb; Joshua J Meeks; Peter H Gann; Virgilia Macias; Andre Kajdacsy-Balla; William J Catalona; Rick Kittles Journal: J Clin Oncol Date: 2016-02-22 Impact factor: 44.544
Authors: Adam B Murphy; Yaw Nyame; Iman K Martin; William J Catalona; Courtney M P Hollowell; Robert B Nadler; James M Kozlowski; Kent T Perry; Andre Kajdacsy-Balla; Rick Kittles Journal: Clin Cancer Res Date: 2014-05-01 Impact factor: 12.531